Trial Profile
A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients with Late Stage Acute Myeloid Leukaemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs Elacytarabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms CLAVELA
- Sponsors Aqualis
- 19 May 2014 Final results published in the Journal of Clinical Oncology.
- 01 Apr 2013 Primary endpoint 'Superiority of elacytarabine to investigator's choice of treatment in overall survival rate' has not been met, according to a Clavis pharma media release.
- 01 Apr 2013 Top-line results reported in a Clavis Pharma media release.